证券日报网讯2月25日，戴维医疗（300314）在互动平台回答投资者提问时表示，截至2026年2月13日， 公司股东总户数约为18600户。 ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向戴维医疗提问："尊敬的董秘你好，请问截止至2月20日（2月13日收盘）公司股 东人数为多少，谢谢！" 针对上述提问，戴维医疗回应称："您好，截至2026年2月13日，公司股东总户数约为18600户左右，感 谢您的关注。" ...

Group 1 - The core point of the article is that David Medical (300314) has approximately 18,800 shareholders as of February 10, 2026 [1]

Core Insights - The core viewpoint of the article highlights the growing popularity of spectral therapy technology due to its non-drug, non-invasive, and low side-effect characteristics, leading to increased market penetration from professional medical institutions to home and personal consumption scenarios [1] Industry Overview - Spectral therapy devices utilize specific wavelengths (0.4-3.6μm) to irradiate the human body, achieving therapeutic purposes through photothermal effects, photochemical actions, and biological stimulation [2] - Common product names include visible light therapy devices, photon therapy devices, and red/blue light therapy devices [2] Market Size - The market size of China's spectral therapy device industry is projected to reach 244 million yuan in 2024, with a year-on-year growth of 3.83%, driven by the expansion of medical beauty demand, grassroots medical equipment upgrade policies, and consumption upgrades [8][9] Key Companies - Shenzhen Pumen Technology Co., Ltd. has obtained Class II medical device registration for its spectral therapy devices, covering multiple wavelengths [9] - Ningbo David Medical Co., Ltd. specializes in neonatal jaundice treatment devices using patented spectral technology [10] Industry Development Trends 1. **Technological Integration and Innovation**: The industry is transitioning from single-wavelength output to multi-spectral dynamic combinations, integrating AI for personalized treatment plans [11] 2. **Application Scenario Extension**: The use of spectral therapy devices is expanding from cosmetic applications to serious medical treatments, including tumor adjuvant therapy and chronic pain management [12] 3. **Industry Structure Reconstruction**: The industry is experiencing consolidation, with stricter regulations leading to increased market share for leading companies, while smaller brands may exit due to insufficient technological investment [13]

Group 1 - The company, David Medical, announced a change in its production scope to include "Class II: 15-01 - Operating Tables" [1] - The company has obtained a revised Medical Device Production License issued by the Zhejiang Provincial Drug Administration [1]

许可证编号：浙药监械生产许20100125号 证券代码：300314 证券简称：戴维医疗 公告编号：2026-006 宁波戴维医疗器械股份有限公司 关于变更医疗器械生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）因生产经营需要， 对生产范围进行了变更，在原有基础上增加了"第Ⅱ类：15-01-手术台"， 并于近日取得了由浙江省药品监督管理局颁发的变更后的《医疗器械生产许 可证》。变更后的具体信息如下： 生产范围：第Ⅲ类：08-03-急救设备；第Ⅱ类：02-12-手术器械-穿刺 导引器，02-13-手术器械-吻（缝）合器械及材料，07-03-生理参数分析测 量设备，07-04-监护设备，08-03-急救设备，08-05-呼吸、麻醉、急救设备 辅助装置，08-07-医用供气排气相关设备，09-02-温热（冷）治疗设备/器 具，09-03-光治疗设备，14-06-与非血管内导管配套用体外器械，14-15- 病人护理防护用品，15-01-手术台，15-05-患者转运器械*** 许可期限：自2025年1月1 ...

Group 1 - The core point of the article is that David Medical (300314) has approximately 18,600 shareholders as of January 30, 2026 [1]

Group 1 - The core point of the article is that David Medical responded to an investor inquiry regarding the number of shareholders as of January 31, 2026, stating that the total number of shareholders is approximately 18,600 [1] Group 2 - The company expressed gratitude for the investor's interest in their shareholder information [1]

Core Viewpoint - David Medical announced an expected net profit attributable to shareholders of 75 million to 95 million yuan for the fiscal year 2025, representing a growth of 30.97% to 65.90% compared to the previous year's profit of 57.26 million yuan [1] Financial Performance - The projected net profit for 2025 is estimated to be between 75 million and 95 million yuan [1] - This represents an increase of 30.97% to 65.90% from the previous year's net profit of 57.26 million yuan [1]

Core Viewpoint - David Medical has announced its annual performance forecast, expecting a significant increase in net profit for 2025, indicating strong growth potential in its operations and market expansion efforts [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 75 million to 95 million yuan for 2025, representing a year-on-year increase of 30.97% to 65.90% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 56.25 million and 76.25 million yuan, reflecting a year-on-year growth of 7.76% to 46.08% [1] Market Strategy - During the reporting period, the company has further solidified its existing market position while continuously enhancing its efforts in both domestic and international market expansion [1] - The company's main business revenue has shown steady growth, supported by increased investment income compared to the previous year [1]